Toward imaging of alpha-synuclein with PET
- PMID: 37541192
- DOI: 10.1016/j.cell.2023.06.018
Toward imaging of alpha-synuclein with PET
Abstract
Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests K.K. reports financial support was provided by National Institutes of Health. K.K. reports a relationship with Biogen Inc that includes non-financial support. Research support was also provided by Eli Lilly.
Comment on
-
Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies.Cell. 2023 Aug 3;186(16):3350-3367.e19. doi: 10.1016/j.cell.2023.06.004. Epub 2023 Jul 7. Cell. 2023. PMID: 37421950 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
